In rats treated with doxorubicin, ET increased PGC-1α levels and prevented FOXO1 and MuRF-1 increase in cardiac muscle and FoxO3, MuRF-1, and BNIP3 increase in skeletal muscle, contributing to mechanisms of reduction of myopathy [55]. The gene discussed is TRIM63; the disease is myopathy.